Nicole Fratini

Nicole Fratini

Auto-generated profile, based on publicly available information

Nicole Fratini

Department of Molecular Medicine, Sapienza University, Viale Regina Elena, 324, 00161, Rome, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in The Journal of Pathology
Verified
Journal Article
Open access
MMMARIKA MILAN
MARIKA MILAN
FMFabio Maiullari
Fabio Maiullari
MCMaila Chirivì
Maila Chirivì
MCMARIA GRAZIA CERAOLO
MARIA GRAZIA CERAOLO
RZRebecca Zigiotto
Rebecca Zigiotto
RRRoberto Rizzi
Roberto Rizzi
Duchenne muscular dystrophy (DMD) is caused by the absence of the full form of the dystrophin protein, which is essential for maintaining the structural integrity of muscle cells, including those in the heart and respiratory system. Despite progress in understanding the molecular mechanisms associated with DMD, myocardial insufficiency persists as the primary cause of mortality, and existing therapeutic strategies remain limited. This study investigates the hypothesis that a dysregulation of the biological communication between infiltrating macrophages (MPs) and neurocardiac junctions exists in dystrophic cardiac tissue. In a mouse model of DMD ( mdx ), this phenomenon is influenced by the over‐release of chondroitin sulfate proteoglycan‐4 (CSPG4), a key inhibitor of nerve sprouting and a modulator of the neural function, by MPs infiltrating the cardiac tissue and associated with dilated cardiomyopathy, a hallmark of DMD. Givinostat, the histone deacetylase inhibitor under current development as a clinical treatment for DMD, is effective at both restoring a physiological microenvironment at the neuro‐cardiac junction and cardiac function in mdx mice in addition to a reduction in cardiac fibrosis, MP‐mediated inflammation, and tissue CSPG4 content. This study provides novel insight into the pathophysiology of DMD in the heart, identifying potential new biological targets. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

27 May 2025 in Biomaterials
Verified
Journal Article
Open access
FMFabio Maiullari
Fabio Maiullari
MCMaria Grazia Ceraolo
Maria Grazia Ceraolo
DPDario Presutti
Dario Presutti
NFNicole Fratini
Nicole Fratini
MGMatteo Galbiati
Matteo Galbiati
RRRoberto Rizzi
Roberto Rizzi
The development of advanced in vitro systems to replicate vascularized tissue environments is critical for studying cancer progression, immune interactions, and therapeutic responses. Traditional models often lack physiological perfusion, scale flexibility, and compatibility with complex microenvironments, limiting their translational impact. The small Vessel Environment Bioreactor (sVEB) represents a promising advancement in microfluidic and organ-on-chip technologies, enabling the replication of dynamic environments that mimic key features of vascular and tumor biology. Validated through in vitro experiments and computational flow simulations, the sVEB supports vascular network formation, dynamic cell cultures, and tumor-immune interactions. iPSC-derived endothelial cells in the sVEB formed stable perfusable microvessels with secondary branching into the surrounding matrix, while fluidic simulations confirmed laminar flow and shear stress conditions compatible with physiological parameters. In parallel, breast cancer organoids were assembled within the hydrogel compartment surrounding the sVEB and cultured under dynamic flow conditions. Moreover, CD8+ T lymphocytes were delivered using a magnetic nanoparticle-based approach, enabling immune-tumor contact within the model. Advancing this technology will require continued efforts on biomaterial development, integration of patient-derived cells, and standardized protocols to ensure scalability and reproducibility, ultimately establishing the sVEB as a versatile platform for precision medicine capable of modeling patient-specific microenvironments to support the discovery of innovative therapeutic approaches.